



Two significant nominations for Collectis:

Professor Alain Fischer joins the Scientific Advisory Board

and

Alain Godard joins the Board of Directors

Biocitech, December 10th 2007 – Collectis S.A., the genome engineering company developing a new range of custom DNA rewriting products for the healthcare, research and industrial sectors, today announced two significant nominations. Professor Alain Fischer will join the company's Scientific Advisory Board, whilst Alain Godard (a former President of the Executive Board at Aventis CropSciences) joins the Collectis Board of Directors as an independent member.

"We are very honored by the fact that Professor Alain Fischer – a world-famous specialist in immunology and gene therapy – has agreed to join our Scientific Advisory Board" stated Frédéric Pâques, Chief Scientific Officer at Collectis. He added that "Professor Fischer's internationally renowned work on immune diseases and his innovative approach to finding effective treatments for these conditions will further reinforce our therapeutic development strategy".

Professor Alain Fischer thus becomes the eighth member of the Collectis' Scientific Advisory Board, whose members stand out in terms of their active contribution to the development and optimization of the company's technology. By way of an example, Prof. Fischer and his group at INSERM Unit U768 at the Necker Children's Hospital are currently trialing a meganuclease targeting the gene IL2RG and assessing its ability to repair the defective gene in cell lines carrying an X-SCID mutation.

Alain Godard has been appointed to the Collectis Board of Directors by cooptation and fills the vacancy left by the resignation of Edmond Rothschild Investment Partners (ERIP). The Board of Directors (chaired by Christian Policard) and André Choulika (the company's co-founder and CEO) gave their heartfelt thanks to ERIP (and most particularly to Gilles Nobécourt, its permanent representative) for its commitment to the company and its proactive support over the previous five years. "We are delighted that Alain Godard has agreed to join Collectis as an independent Board member", commented Christian Policard. He added, "Alain Godard's extensive experience of the agrobiotech industry will help Collectis to better leverage its technology and develop its strategic positioning in this field". Alain Godard commented that "Collectis' technologies herald a revolution in plant improvement. The resulting high-precision gene surgery opens up the way to true "plant genomic surgery", which should eventually reconcile the seed companies, the scientists and civil society around the issue of plant biotechnology".

With respect to these two nominations, André Choulika stated that "as it grows, Collectis also needs to evolve, and the appointment of experts like Professor Alain Fischer and Alain Godard to our key Boards means that we are not only reinforcing our leadership in this industry but also demonstrating the potential for downstream integration of our technology. Alain Godard will provide us with essential insight into the agrobiotech industry and help us set our sights in the sector. Professor Alain Fischer will contribute to the implementation of our technology in orphan medical applications and those where our technology can deliver novel potential solutions. This also marks an international-level validation of a new biotech industry segment that we have been pioneering. Our corporate governance structures are moving into a new phase".

Professor Alain Fischer MD has been Head of the Immunology and Pediatric Hematology Service at Necker Children's Hospital since 1996 and serves as Director of the INSERM Unit U768 on "Normal and Pathological Development of the Immune System". He is also a Member of the French Academy of Science and the European Molecular Biology Organisation (EMBO).

